	US 12,121,535 B2
	Therapeutic pharmaceutical composition for cancer including miRNA
Hidetoshi Tahara, Hiroshima (JP); Masaki Kinehara, Hiroshima (JP); and Yuki Yamamoto, Hiroshima (JP)
Assigned to PURMX THERAPEUTICS, INC., Hiroshima (JP)
Filed by PURMX THERAPEUTICS, INC., Hiroshima (JP)
Filed on Mar. 15, 2022, as Appl. No. 17/695,079.
Application 17/695,079 is a division of application No. 16/760,817, granted, now 11,311,568, previously published as PCT/JP2018/041139, filed on Nov. 6, 2018.
Claims priority of application No. 2017-216336 (JP), filed on Nov. 9, 2017.
Prior Publication US 2022/0202848 A1, Jun. 30, 2022
Int. Cl. C07H 21/04 (2006.01); A61K 31/713 (2006.01); A61K 47/42 (2017.01); A61P 35/00 (2006.01); C12N 15/113 (2010.01); A61K 45/06 (2006.01)

CPC A61K 31/713 (2013.01) [A61K 47/42 (2013.01); A61P 35/00 (2018.01); C12N 15/113 (2013.01); A61K 45/06 (2013.01); C12N 2310/141 (2013.01)]

10 Claims

1. A cancer therapy method,

the method comprising administering to a cancer patient a therapeutically effective amount of an anti-cancerous pharmaceutical composition comprising an RNA, which functions as a mature-miRNA, wherein the RNA comprises:

(i) a mature-miRNA consisting of the sequence of SEQ ID NO:11;

(ii) a mature-miRNA consisting of the sequence of SEQ ID NO: 11 having a substitution, addition, and/or deletion of 1-2 bases and having a cancer therapeutic effect; or

(iii) an RNA consisting of a sequence having 90% or more sequence identity to a mature-miRNA consisting of the sequence of SEQ ID NO:11 and having a cancer therapeutic effect,

wherein said cancer is a solid cancer.